Brian D. Kavanagh

Active 1992–2024

75
Papers
19,249
Citations
61
h-index
73
i10-index

Citations

Citations per year for Brian D. Kavanagh1995: 2 citations1996: 3 citations1997: 3 citations1998: 3 citations1999: 14 citations2000: 8 citations2001: 17 citations2002: 11 citations2003: 20 citations2004: 18 citations2005: 22 citations2006: 30 citations2007: 35 citations2008: 53 citations2009: 84 citations2010: 112 citations2011: 126 citations2012: 123 citations2013: 112 citations2014: 137 citations2015: 125 citations2016: 129 citations2017: 134 citations2018: 172 citations2019: 625 citations2020: 723 citations2021: 617 citations2022: 408 citations2023: 226 citations2024: 456 citations2025: 156 citations2026: 3 citations

Citation sources

Countries

World map of the countries and regions citing this authorUnited States: 1,683 citing papers, 29.7% of this breakdownChina: 438 citing papers, 7.7% of this breakdownItaly: 359 citing papers, 6.3% of this breakdownCanada: 308 citing papers, 5.4% of this breakdownNetherlands: 287 citing papers, 5.1% of this breakdownGermany: 284 citing papers, 5% of this breakdownUnited Kingdom: 265 citing papers, 4.7% of this breakdownSwitzerland: 206 citing papers, 3.6% of this breakdownFrance: 196 citing papers, 3.4% of this breakdownJapan: 168 citing papers, 3% of this breakdownAustralia: 148 citing papers, 2.6% of this breakdownSpain: 135 citing papers, 2.4% of this breakdown
0%29.7%Other 21.1%

Fields

  • Medicine77%
  • Physics and Astronomy12.6%
  • Biochemistry, Genetics and Molecular Biology5.3%
  • Immunology and Microbiology2.7%
  • Engineering0.6%
  • Agricultural and Biological Sciences0.3%
  • Other1.5%

Topics

  • Advanced Radiotherapy Techniques9.3%
  • Lung Cancer Diagnosis and Treatment6.9%
  • Lung Cancer Treatments and Mutations5.9%
  • Hepatocellular Carcinoma Treatment and Prognosis5.7%
  • Brain Metastases and Treatment4.5%
  • Lung Cancer Research Studies4.4%
  • Other63.3%

Coauthors

All papers

Open in search
  1. Local Consolidative Therapy Vs. Maintenance Therapy or Observation for Patients With Oligometastatic Non–Small-Cell Lung Cancer: Long-Term Results of a Multi-Institutional, Phase II, Randomized Study

    Authors: , , , , , , , , , , , , , , , , , , , , - Journal of Clinical Oncology 2019 cited by 1,270

  2. Stereotactic body radiation therapy: The report of AAPM Task Group 101

    Authors: , , , , , , , , , , , , , , , , , , , , , , , - Medical Physics 2010 cited by 2,175

  3. Local consolidative therapy versus maintenance therapy or observation for patients with oligometastatic non-small-cell lung cancer without progression after first-line systemic therapy: a multicentre, randomised, controlled, phase 2 study

    Authors: , , , , , , , , , , , , , , , , , , , , , , , - The Lancet Oncology 2016 cited by 1,086

  4. Local Ablative Therapy of Oligoprogressive Disease Prolongs Disease Control by Tyrosine Kinase Inhibitors in Oncogene-Addicted Non–Small-Cell Lung Cancer

    Authors: , , , , , , , , , , - Journal of Thoracic Oncology 2012 cited by 677

  5. Management of Brain Metastases in Tyrosine Kinase Inhibitor–Naïve Epidermal Growth Factor Receptor–Mutant Non–Small-Cell Lung Cancer: A Retrospective Multi-Institutional Analysis

    Authors: , , , , , , , , , , , , , , , , , , , , - Journal of Clinical Oncology 2017 cited by 461

  6. Impact of Radiation Dose to the Host Immune System on Tumor Control and Survival for Stage III Non-Small Cell Lung Cancer Treated with Definitive Radiation Therapy

    Authors: , , , , - International Journal of Radiation Oncology*Biology*Physics 2019 cited by 168

  7. Evaluation of First-line Radiosurgery vs Whole-Brain Radiotherapy for Small Cell Lung Cancer Brain Metastases

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Kenneth Bernstein, Joshua S. Silverman, Inga S. Grills, Z.A. Siddiqui, Justin C. Yuan, Jason P. Sheehan, Diogo Cordeiro, Kename Nosaki, T. Seto, Christopher P. Deibert, Vivek Verma, Samuel E. Day, Lia M. Halasz, Ronald E. Warnick, Daniel M. Trifiletti, Joshua D. Palmer, Albert Attia, Benjamin Li, Christopher P. Cifarelli, Paul D. Brown, John A. Vargo, Stephanie E. Combs, Kerstin A. Kessel, Stefan Rieken, Samir Patel, Matthias Gückenberger, Nicolaus Andratschke, Brian D. Kavanagh, Tyler P. Robin - JAMA Oncology 2020 cited by 215

  8. Radiation-Associated Liver Injury

    Authors: , , , , , , - International Journal of Radiation Oncology*Biology*Physics 2010 cited by 778

  9. High Dose per Fraction, Hypofractionated Treatment Effects in the Clinic (HyTEC): An Overview

    Authors: , , , , , - International Journal of Radiation Oncology*Biology*Physics 2021 cited by 141

  10. American Society for Therapeutic Radiology and Oncology (ASTRO) and American College of Radiology (ACR) Practice Guideline for the Performance of Stereotactic Body Radiation Therapy

    Authors: , , , , , , , , , , , - International Journal of Radiation Oncology*Biology*Physics 2010 cited by 666

  11. Extended Survival and Prognostic Factors for Patients With ALK-Rearranged Non–Small-Cell Lung Cancer and Brain Metastasis

    Authors: , , , , , , , , , , , , , , , - Journal of Clinical Oncology 2015 cited by 331

  12. CTLA4 blockade expands FoxP3+ regulatory and activated effector CD4+ T cells in a dose-dependent fashion

    Authors: , , , , , , , , - Blood 2008 cited by 253

  13. Multi-Institutional Phase I/II Trial of Stereotactic Body Radiation Therapy for Lung Metastases

    Authors: , , , , , , , , , - Journal of Clinical Oncology 2009 cited by 1,095

  14. Multi-Institutional Phase I/II Trial of Stereotactic Body Radiation Therapy for Liver Metastases

    Authors: , , , , , , , , , , , - Journal of Clinical Oncology 2009 cited by 804

  15. Stereotactic Body Radiation Therapy in Multiple Organ Sites

    Authors: , , , , - Journal of Clinical Oncology 2007 cited by 443

  16. Radiation-Associated Kidney Injury

    Authors: , , , , , , , , - International Journal of Radiation Oncology*Biology*Physics 2010 cited by 312

  17. Combination of Trastuzumab Emtansine and Stereotactic Radiosurgery Results in High Rates of Clinically Significant Radionecrosis and Dysregulation of Aquaporin-4

    Authors: , , , , , , , , , , , , , , , - Clinical Cancer Research 2019 cited by 72

  18. Phase II Trial of Stereotactic Body Radiation Therapy Combined With Erlotinib for Patients With Limited but Progressive Metastatic Non–Small-Cell Lung Cancer

    Authors: , , , , , , , , , , , , , , - Journal of Clinical Oncology 2014 cited by 285

  19. Natural History and Factors Associated with Overall Survival in Stage IV ALK-Rearranged Non–Small Cell Lung Cancer

    Authors: , , , , , , , , , , , , , , - Journal of Thoracic Oncology 2018 cited by 145

  20. Radiation Dose–Volume Effects in the Stomach and Small Bowel

    Authors: , , , , , , - International Journal of Radiation Oncology*Biology*Physics 2010 cited by 548

  21. Stereotactic body radiotherapy for colorectal liver metastases

    Authors: , , , , , , , , , , - Cancer 2011 cited by 299

  22. Practice Recommendations for Lung Cancer Radiotherapy During the COVID-19 Pandemic: An ESTRO-ASTRO Consensus Statement

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Sue S. Yom, David A. Palma - International Journal of Radiation Oncology*Biology*Physics 2020 cited by 227

  23. Results of a Multi-Institutional Phase 2 Clinical Trial for 4DCT-Ventilation Functional Avoidance Thoracic Radiation Therapy

    Authors: , , , , , , , , , , , , , , , , , - International Journal of Radiation Oncology*Biology*Physics 2021 cited by 66

  24. Quality and safety considerations in stereotactic radiosurgery and stereotactic body radiation therapy: Executive summary

    Authors: , , , , , , , , - Practical Radiation Oncology 2011 cited by 209